Your browser doesn't support javascript.
loading
IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis.
Grolleau, Chloé; Calugareanu, Andreea; Demouche, Sarah; Nosbaum, Audrey; Staumont-Sallé, Delphine; Aubert, Hélène; Cassius, Charles; Jachiet, Marie; Saussine, Anne; Bagot, Martine; Bachelez, Hervé; Battistella, Maxime; Hotz, Claire; Du Thanh, Aurélie; Crépy, Marie-Noëlle; Bergerat, David; Merandet, Marine; Onifarasoaniaina, Rachel; Alberdi, Antonio; How-Kit, Alexandre; Bouaziz, Jean-David; Le-Buanec, Hélène.
Afiliación
  • Grolleau C; Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
  • Calugareanu A; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France; Dermatology Department, University Hospital of Lyon, Lyon, France.
  • Demouche S; Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
  • Nosbaum A; Dermatology Department, University Hospital of Lyon, Lyon, France.
  • Staumont-Sallé D; Dermatology Department, U1286 Inserm Lille Inflammation Translational Research Institute, University of Lille, Lille, France.
  • Aubert H; Dermatology Department, University Hospital of Nantes, Nantes, France.
  • Cassius C; Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
  • Jachiet M; Dermatology Department, Saint Louis Hospital, Paris, France.
  • Saussine A; Dermatology Department, Saint Louis Hospital, Paris, France.
  • Bagot M; Dermatology Department, Saint Louis Hospital, Paris, France.
  • Bachelez H; Dermatology Department, Saint Louis Hospital, Paris, France; Laboratory of Genetic of Skin Diseases, INSERM U1163, Imagine Institute, University of Paris, Paris, France.
  • Battistella M; Pathology Department, Saint Louis Hospital, Paris, France.
  • Hotz C; Dermatology Department, Henri Mondor Hospital, Créteil, France.
  • Du Thanh A; Dermatology Department, University Hospital of Montpellier, Montpellier, France.
  • Crépy MN; Dermatology Department, Paris University Hospital of Cochin, Paris, France.
  • Bergerat D; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
  • Merandet M; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
  • Onifarasoaniaina R; INSERM U1016, CNRS UMR8104, Cochin Institute, University of Paris, Paris, France.
  • Alberdi A; Technological Platerform of Saint- Louis Research Institute (IRSL), Saint-Louis Hospital, University of Paris, Paris, France.
  • How-Kit A; Laboratory of Genomics, Foundation Jean Dausset (CEPH), Paris, France.
  • Bouaziz JD; Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France. Electronic address: jean-david.bouaziz@aphp.fr.
  • Le-Buanec H; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
J Invest Dermatol ; 143(5): 711-721.e7, 2023 05.
Article en En | MEDLINE | ID: mdl-36610660
Dupilumab is a therapeutic antibody targeting IL-4 and IL-13 receptor subunit alpha used for the treatment of patients with atopic dermatitis (AD). Cases of psoriasis-like reactions induced under dupilumab treatment (dupilumab-induced psoriatic eruption [DI-Pso]) for AD were recently reported. To understand the pathogenesis of DI-Pso, we performed gene expression profiling studies on skin biopsies of DI-Pso (n = 7) compared with those of plaque psoriasis, AD, and healthy controls (n = 4 each). Differential gene expression was performed using enrichment and Gene Ontology analysis. Gene expression was validated by qPCR, and protein levels were assessed by immunohistochemistry. Transcriptomic and protein analysis of DI-Pso compared with that of healthy controls, plaque psoriasis, and AD skins revealed activation of T helper 17/IL-23 pathways associated with a significant expression of IL-36, surrogate marker of pustular psoriasis. By contrast, T helper 2 representative genes' expression was strongly decreased in DI-Pso across comparison. Matching analysis with public data of pustular psoriasis skin corroborated that DI-Pso and pustular psoriasis upstream regulators overlap, greater than the overlap with plaque psoriasis. Furthermore, DI-Pso showed strongly decreased expression of many barrier skin genes compared with healthy controls, plaque psoriasis, and AD. Our data indicate that the pathogenesis of DI-Pso relied on a shift of skin immune responses from a T helper 2 to an IL-36 and T helper 17 polarization and on intensified skin barrier alterations.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Dermatitis Atópica / Exantema Límite: Humans Idioma: En Revista: J Invest Dermatol Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Dermatitis Atópica / Exantema Límite: Humans Idioma: En Revista: J Invest Dermatol Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos